Scaling antibody testing and immunity tracking by digitising test results

通过数字化测试结果来扩展抗体测试和免疫追踪

• 批准号: 61618
• 金额: $ 14.1万
• 依托单位: VITAL SIGNS SOLUTIONS LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=61618
• 关键词: Scaling; antibody; testing; immunity; tracking

As a result of Innovate UK funding, we have been successful in hitting the objectives of adapting our existing technology and developed an app to digitise the results of Covid-19 rapid testing. We have secured an exclusive partnership with a major UK-based test manufacturer that gives us access to a number of world-leading tests including a CE-marked, triple antibody test, which tests for 3 antibodies, including early onset IgA antibody, which if present, indicates an active Covid-19 infection. We believe that as infection rates rise across the UK and Europe, there are large constituent groups who cannot work from home and have to enter the workplace and ensuring they do so safely is an area where rapid testing could be of massive benefit very quickly. This includes teachers, travel (e.g. airports, airlines), food preparation, manufacturing and hospitality, among others, who would benefit from a cost-effective rapid testing solution to provide results in minutes. However, without a full solution that includes the test, screening staff and a digital platform to collect test results, additional information and demographic data, it is virtually impossible to get true value from rapid testing. Further, if an employer, or workplace operator wants to understand the health of their workforce in some detail, without a digital platform and some kind of dashboard or report to collate the data from a screening, that is impossible. We believe we have two major pieces of the puzzle, namely access to world leading tests and a digital platform, via the app that was developed as part of the previous grant. We now want to focus on how rapid testing can be scaled within workforces that have to go to work and cannot work from home, to help keep workplaces Covid-free and stem the growth of the virus. We also believe that the data we will be collecting will be of value to a number of healthcare organisations, which will require sufficient interoperability in our cloud infrastructure to be able to do this efficiently.We believe we need to move quickly to prove beyond reasonable doubt that a digitally enabled rapid testing solution can be used as of now to help keep Britain working.

由于创新英国的资助，我们成功实现了调整现有技术的目标，并开发了一款应用程序，将新冠病毒快速检测结果数字化。我们已与一家主要的英国测试制造商建立独家合作伙伴关系，使我们能够获得多项世界领先的测试，包括CE认证的三重抗体测试，该测试可检测3种抗体，包括早发性伊加抗体，如果存在，则表明活动性Covid-19感染。我们认为，随着英国和欧洲各地感染率的上升，有大量的组成群体不能在家工作，必须进入工作场所，确保他们安全地这样做是一个快速检测可能很快带来巨大好处的领域。这包括教师、旅行（如机场、航空公司）、食品准备、制造业和酒店业等，他们将受益于具有成本效益的快速检测解决方案，在几分钟内提供结果。然而，如果没有一个完整的解决方案，包括测试，筛查人员和数字平台来收集测试结果，额外的信息和人口统计数据，几乎不可能从快速测试中获得真正的价值。此外，如果雇主或工作场所运营商希望详细了解其员工的健康状况，而没有数字平台和某种仪表板或报告来整理筛选数据，那是不可能的。我们相信我们有两个主要的拼图，即通过作为先前赠款的一部分开发的应用程序访问世界领先的测试和数字平台。我们现在希望关注如何在必须上班而不能在家工作的劳动力中扩大快速检测，以帮助保持工作场所无新冠病毒并阻止病毒的增长。我们还相信，我们将收集的数据将对许多医疗机构有价值，这将需要我们的云基础设施具有足够的互操作性，以便能够有效地做到这一点。我们相信，我们需要迅速采取行动，以证明从现在起，数字化的快速检测解决方案可以用于帮助英国保持运转。